Italy Medical Devices Market Report 2026: EU MDR, BDNM Registration, and Regional Hospital Procurement Intelligence

The Italian medical devices market is estimated at EUR 12–14 billion in 2026, making it the fourth-largest medical device market in the EU. Italy is both a significant consumer and manufacturer of medical devices — hosting over 4,500 medtech companies, predominantly SMEs concentrated in Lombardy, Emilia-Romagna, and Veneto. Italy is particularly strong in orthopaedics, dental devices, cardiology, and diagnostics manufacturing. The market is split approximately 60% hospital/clinical (ASL and AO procurement channels) and 40% outpatient/retail (reimbursed through regional SSN budgets).

Italy's national competent authority for medical devices is the Ministero della Salute (Ministry of Health), acting through its Direzione Generale dei Dispositivi Medici and the BDNM (Banca Dati Nazionale dei Dispositivi Medici) registration database. All medical devices placed on the Italian market must have CE marking (EU MDR 2017/745 for medical devices; IVDR 2017/746 for in vitro diagnostics) and be registered in the BDNM. Importers and distributors must also register in Italy's BSDI (Banca Dati dei Soggetti del Sistema Distributivo). Manufacturers of custom-made devices have specific Italian declaratory obligations. The Ministero della Salute manages vigilance reporting and coordinates with SCENIHR and MDCG at EU level.

Hospital devices in Italy are primarily funded within DRG (Diagnosis-Related Group) tariffs set by the DRG system (Raggruppamenti Omogenei di Diagnosi, ROD). High-cost implants and innovative devices not covered within standard DRG tariffs may be separately reimbursed through regional budget allocations or via national ministerial authorisations (ex-art 1 comma 4 D.L. 347/2001 pathway for innovative devices). Unlike France, Italy does not have a single national add-on payment pathway comparable to NUB or Forfait Innovation — reimbursement for novel devices above the DRG bundle often requires individual regional negotiations or hospital budget allocations. The fragmented regional system means that penetrating Italy requires hospital-by-hospital and region-by-region access strategies.

The five largest Italian medical device segments by value are: orthopaedics and trauma (Italy has one of Europe's highest joint replacement rates; strong domestic manufacturing in Emilia-Romagna); in vitro diagnostics (laboratory analysers, molecular diagnostics, immunochemistry systems); cardiovascular devices (stents, cardiac rhythm management, heart failure monitoring); surgical instruments and robotics (da Vinci expansion across major university centres); and diagnostic imaging (MRI, CT, ultrasound — Italy has significant imaging capacity in both public and private accredited hospitals). Aesthetic medicine devices and ophthalmology are also significant sectors given Italy's strong private medical aesthetic market.

Italy's regional procurement organisations play a critical role in medical device purchasing, as regional health budgets (SSN regionali) fund the majority of hospital device expenditure. Major regional purchasing consortia include: Intercent-ER (Emilia-Romagna) — one of Italy's most active and centralised regional procurement bodies; ARCA (Lombardy); ESTAR (Tuscany); SoReSa (Campania); and Consip (national framework contracts for some device categories). Regional tender decisions at these consortia can unlock access to hundreds of hospital facilities simultaneously — making consortium tender outcomes critical commercial milestones for device manufacturers entering or defending position in the Italian hospital market. Because each consortium runs its own technical specification and award calendar, manufacturers competing across several regions typically need distributor coverage or a direct commercial presence capable of bidding in parallel processes rather than relying on a single national procurement route.

Under EU MDR 2017/745, manufacturers must complete a conformity assessment appropriate to the device's risk classification — Class I, IIa, IIb, or III — before affixing CE marking and placing a device on the Italian market. Class I devices without a measuring or sterile function may self-certify, while higher-risk classes require a Notified Body audit of the technical documentation and the manufacturer's ISO 13485 quality management system. MDR transitional provisions under Regulation (EU) 2023/607 allow devices still certified under the legacy MDD directive to remain on the market through 2027 (Class III and implantable devices) or 2028 (other classes), provided no significant design change occurs and a Notified Body agreement is in place. Once CE-marked, manufacturers, authorised representatives, importers, and distributors operating in Italy must register with the Ministero della Salute in the BDNM and, as EUDAMED phases in fully, in the corresponding EU-level database. Manufacturers should generally budget 12–24 months to complete CE certification and the associated Italian registration steps for higher-risk device classes.

Public medical device procurement in Italy is governed by the Codice dei Contratti Pubblici (Legislative Decree 36/2023), with tenders published on regional and national e-procurement portals and tracked through a mandatory CIG (Codice Identificativo di Gara) code. Consip, the national central purchasing body owned by Italy's Ministry of Economy and Finance, negotiates framework agreements ("convenzioni" and "accordi quadro") for standardised device categories that hospitals and regions may optionally adhere to, but the bulk of clinical device spend is tendered through regional central purchasing bodies such as Intercent-ER, ARCA, ESTAR, and SoReSa. Contracts above EU value thresholds must additionally be advertised on TED (Tenders Electronic Daily) for cross-border visibility, and bidding suppliers are generally expected to demonstrate ANAC (Autorità Nazionale Anticorruzione) qualification and DURC (Documento Unico di Regolarità Contributiva) compliance. Because tender calendars, technical specifications, and CND-code eligibility criteria are set independently by each regional consortium, successful market entry usually requires a coordinated multi-region bidding strategy rather than a single national submission.

Devices supplied for outpatient or home-care use and billed directly to the SSN must be listed in the Repertorio dei Dispositivi Medici, the national reimbursement catalogue maintained by the Ministero della Salute, which is distinct from the BDNM market-placement registry used for regulatory tracking. Hospital-based devices are typically bundled within DRG tariffs, so day-to-day reimbursement in practice depends heavily on regional health budget allocations (SSN regionali) rather than a single uniform national tariff, and some regions supplement DRG funding with dedicated innovation budgets for high-value implants and novel technologies. Because responsibility for health spending sits with Italy's 21 regions, the pace and generosity of device funding varies significantly between wealthier northern regions such as Lombardy, Emilia-Romagna, and Veneto and southern regions operating under budget recovery plans (piani di rientro). AIFA remains the national authority for pharmaceuticals, but for devices the Ministero della Salute and its technical advisory bodies oversee nomenclature and repertoire updates. Manufacturers seeking systematic reimbursement should plan for both national repertoire listing and region-by-region hospital budget negotiation.

BioNixus delivers medical device market research in italy: regulator-aware access intelligence, hospital consumption analogues, physician and payer qualitative programmes, and launch evidence under EphMRA and BHBIA governance with GDPR-aligned fieldwork for multinational sponsors. Teams receive decision-ready outputs validated against national policy and institution-level adoption—not desk extrapolation from unrelated regions.

BioNixus supports italy-based medical device companies expanding into GCC and MENA markets with SFDA and MOHAP regulatory intelligence, NUPCO and hospital procurement tracking in Saudi Arabia, UAE insurer and formulary research, physician panels across GCC countries, and comparative italy versus GCC market intelligence. GCC expansion is a distinct service line with its own tender and access calendars—see our GCC pharmaceutical market report for regional context. Launch assumptions should be validated market by market rather than from a single Gulf average.